半胱氨酸代谢途径调控与肿瘤治疗新策略

解放; 刘楠

doi:10.11665/j.issn.1000-5048.20210502

半胱氨酸代谢途径调控与肿瘤治疗新策略

解放,
刘楠

中国药科大学生命科学与技术学院，南京 211198

基金项目: 国家重点研发计划资助项目（No.2018YFA0902000）

计量
- 文章访问数: 488
- HTML全文浏览量: 17
- PDF下载量: 1061
出版历程
- 收稿日期: 2021-03-12
- 修回日期: 2021-04-14
- 刊出日期: 2021-10-24

Regulation of cysteine metabolism and new strategies for cancer treatment

XIE Fang,
LIU Nan

School of Life Science & Technology, China Pharmaceutical University, Nanjing 211198, China

Funds: This work was supported by the National Key Research and Development Program of China (No.2018YFA0902000)

摘要

摘要: 肿瘤细胞通过代谢重编程满足其特殊的物质和能量需求。现有肿瘤代谢重编程研究以糖代谢研究为主，而氨基酸代谢在肿瘤细胞的增殖、迁移、侵袭方面也发挥了重要作用，是肿瘤能量代谢研究的新兴热点。半胱氨酸是一种生糖氨基酸，其代谢途径涉及多种酶和产物，可调节诸如氧化应激、能量代谢和细胞自噬等生理和病理过程。本文从肿瘤细胞中半胱氨酸的外源转运和内源性转化途径、半胱氨酸代谢途径对肿瘤发生发展的多种调控机制以及基于半胱氨酸代谢途径的潜在治疗靶点等方面进行了综述，为肿瘤临床用药提供理论依据。
- 代谢重编程 /
- 半胱氨酸 /
- 胱氨酸转运蛋白 /
- 抗肿瘤 /
- 氧化应激
Abstract: In order to sustain prodigious anabolic needs, tumor cells need metabolic reprogramming that differs from untransformed somatic cells.Besides glucose metabolism in tumor, amino acid metabolism also plays an important role in tumor cell proliferation, migration, and invasion.It is an emerging trend in tumor energy metabolism research.The metabolic pathway of cysteine, a glucose-producing amino acid, involves a variety of enzymes and products, regulating physiological and pathological processes such as oxidative stress, energy metabolism, and autophagy.This article focuses on the exogenous transport and endogenous conversion pathways of cysteine in tumor cells, the various regulatory mechanisms of cysteine metabolism pathways on the occurrence and development of tumors, and the potential therapeutic targets based on cysteine metabolism pathways, which can provide a theoretical basis for clinical use of drugs against tumors.
- metabolic reprogramming /
- cysteine /
- cystine transporters /
- antitumor /
- oxidative stress

HTML全文

参考文献(47)

[1]	. Sci Transl Med，2021，13（575）：eaba6110.
[2]	Xia L，Oyang L，Lin J，et al. The cancer metabolic reprogramming and immune response［J］. Mol Cancer，2021，20（1）：28.
[3]	Ekici S，Risk BB，Neill SG，et al. Characterization of dysregulated glutamine metabolism in human glioma tissue with ¹H NMR［J］. Sci Rep，2020，10（1）：20435.
[4]	Salamanca-Cardona L，Shah H，Poot AJ，et al. In vivo imaging of glutamine metabolism to the oncometabolite 2-hydroxyglutarate in IDH1/2 mutant tumors［J］. Cell Metab，2017，26（6）：830-841.e3.
[5]	Fultang L，Gamble LD，Gneo L，et al. Macrophage-derived IL1β and TNFα regulate arginine metabolism in neuroblastoma［J］. Cancer Res，2019，79（3）：611-624.
[6]	Coothankandaswamy V，Cao S，Xu Y，et al. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer［J］. Br J Pharmacol，2016，173（23）：3292-3306.
[7]	Murphy B，Bhattacharya R，Mukherjee P. Hydrogen sulfide signaling in mitochondria and disease［J］. FASEB J，2019，33（12）：13098-13125.
[8]	Bonifácio VDB，Pereira SA，Serpa J，et al. Cysteine metabolic circuitries：druggable targets in cancer［J］. Br J Cancer，2021，124（5）：862-879.
[9]	Okuno S，Sato H，Kuriyama-Matsumura K，et al. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines［J］. Br J Cancer，2003，88（6）：951-956.
[10]	Yan R，Zhao X，Lei J，et al. Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex［J］. Nature，2019，568（7750）：127-130.
[11]	Hansen CG，Ng YLD，Lam WLM，et al. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1［J］. Cell Res，2015，25（12）：1299-1313.
[12]	Bailey CG，Ryan RM，Thoeng AD，et al. Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria［J］. J Clin Invest，2011，121（1）：446-453.
[13]	Kaplan E，Zubedat S，Radzishevsky I，et al. ASCT1 （Slc1a4） transporter is a physiologic regulator of brain d-serine and neurodevelopment［J］. Proc Natl Acad Sci U S A，2018，115（38）：9628-9633.
[14]	Jiang Y，Cao Y，Wang Y，et al. Cysteine transporter SLC3A1 promotes breast cancer tumorigenesis［J］. Theranostics，2017，7（4）：1036-1046.
[15]	Gliddon CM，Shao Z，LeMaistre JL，et al. Cellular distribution of the neutral amino acid transporter subtype ASCT2 in mouse brain［J］. J Neurochem，2009，108（2）：372-383.
[16]	Luo Y，Li W，Ling Z，et al. ASCT2 overexpression is associated with poor survival of OSCC patients and ASCT2 knockdown inhibited growth of glutamine-addicted OSCC cells［J］. Cancer Med，2020，9（10）：3489-3499.
[17]	Yoo HC，Park SJ，Nam M，et al. A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells［J］. Cell Metab，2020，31（2）：267-283.
[18]	Sbodio JI，Snyder SH，Paul BD. Regulators of the transsulfuration pathway［J］. Br J Pharmacol，2019，176（4）：583-593.
[19]	Bhattacharyya S，Saha S，Giri K，et al. Cystathionine beta-synthase （CBS） contributes to advanced ovarian cancer progression and drug resistance［J］. PLoS One，2013，8（11）：e79167.
[20]	Szabo C，Coletta C，Chao C，et al. Tumor-derived hydrogen sulfide，produced by cystathionine-β-synthase，stimulates bioenergetics，cell proliferation，and angiogenesis in colon cancer［J］. Proc Natl Acad Sci U S A，2013，110（30）：12474-12479.
[21]	Zhu J，Berisa M，Schw?rer S，et al. Transsulfuration activity can support cell growth upon extracellular cysteine limitation［J］. Cell Metab，2019，30（5）：865-876.
[22]	Xu Q，Li YY，Gao X，et al. HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer［J］. Nat Commun，2020，11（1）：3978.
[23]	Angelova PR，Abramov AY. Functional role of mitochondrial reactive oxygen species in physiology［J］. Free Radic Biol Med，2016，100：81-85.
[24]	Hong H，Wu H，Chen J，et al. Cytotoxicity induced by iodinated haloacetamides via ROS accumulation and apoptosis in HepG-2 cells［J］. Environ Pollut，2018，242（Pt A）：191-197.
[25]	Stockwell BR，Friedmann Angeli JP，Bayir H，et al. Ferroptosis：a regulated cell death Nexus linking metabolism，redox biology，and disease［J］. Cell，2017，171（2）：273-285.
[26]	Harris IS，Treloar AE，Inoue S，et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression［J］. Cancer Cell，2015，27（2）：211-222.
[27]	Wang L，Liu Y，Du T，et al. ATF₃ promotes erastin-induced ferroptosis by suppressing system Xc［J］. Cell Death Differ，2020，27（2）：662-675.
[28]	Liu X，Olszewski K，Zhang Y，et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer［J］. Nat Cell Biol，2020，22（4）：476-486.
[29]	Machuca-Gayet I，Quinaux T，Bertholet-Thomas A，et al. Bone disease in nephropathic cystinosis：beyond renal osteodystrophy［J］. Int J Mol Sci，2020，21（9）：3109.
[30]	Paul BD，Sbodio JI，Snyder SH. Cysteine metabolism in neuronal redox homeostasis［J］. Trends Pharmacol Sci，2018，39（5）：513-524.
[31]	Wan XM，Zheng F，Zhang L，et al. Autophagy-mediated chemosensitization by cysteamine in cancer cells［J］. Int J Cancer，2011，129（5）：1087-1095.
[32]	Fujisawa T，Rubin B，Suzuki A，et al. Cysteamine suppresses invasion，metastasis and prolongs survival by inhibiting matrix metalloproteinases in a mouse model of human pancreatic cancer［J］. PLoS One，2012，7（4）：e34437.
[33]	Andrzejewska Z，Nevo N，Thomas L，et al. Cystinosin is a component of the vacuolar H⁺-ATPase-ragulator-rag complex controlling mammalian target of rapamycin complex 1 signaling［J］. J Am Soc Nephrol，2016，27（6）：1678-1688.
[34]	Youness RA，Gad AZ，Sanber K，et al. Targeting hydrogen sulphide signaling in breast cancer［J］. J Adv Res，2021，27：177-190.
[35]	Wang YH，Huang JT，Chen WL，et al. Dysregulation of cystathionine γ-lyase promotes prostate cancer progression and metastasis［J］. EMBO Rep，2019，20（10）：e45986.
[36]	Jia M，Qin D，Zhao C，et al. Redox homeostasis maintained by GPX4 facilitates STING activation［J］. Nat Immunol，2020，21（7）：727-735.
[37]	Motwani M，Pesiridis S，Fitzgerald KA. DNA sensing by the cGAS-STING pathway in health and disease［J］. Nat Rev Genet，2019，20（11）：657-674.
[38]	Dai E，Han L，Liu J，et al. Ferroptotic damage promotes pancreatic tumorigenesis through a TMEM173/STING-dependent DNA sensor pathway［J］. Nat Commun，2020，11（1）：6339.
[39]	Shin D，Kim EH，Lee J，et al. Nrf2 inhibition reverses resistance to GPX4 inhibitor-induced ferroptosis in head and neck cancer［J］. Free Radic Biol Med，2018，129：454-462.
[40]	Bi J，Yang S，Li L，et al. Metadherin enhances vulnerability of cancer cells to ferroptosis［J］. Cell Death Dis，2019，10（10）：682.
[41]	Eaton JK，Furst L，Ruberto RA，et al. Selective covalent targeting of GPX4 using masked nitrile-oxide electrophiles［J］. Nat Chem Biol，2020，16（5）：497-506.
[42]	Robert SM，Buckingham SC，Campbell SL，et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma［J］. Sci Transl Med，2015，7（289）：289ra86.
[43]	Chen WT，Liu J. Advances in research on immune checkpoint and its inhibitors in glioma［J］. J China Pharm Univ（中国药科大学学报），2021，52（1）：104-112.
[44]	Tian JP，Zhang J，Zhou JP，et al. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway［J］. J China Pharm Univ（中国药科大学学报），2019，50（1）：1-10.
[45]	Lang X，Green MD，Wang W，et al. Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11［J］. Cancer Discov，2019，9（12）：1673-1685.
[46]	Wang W，Green M，Choi JE，et al. CD8⁺ T cells regulate tumour ferroptosis during cancer immunotherapy［J］. Nature，2019，569（7755）：270-274.
[47]	Su Y，Zhao B，Zhou L，et al. Ferroptosis，a novel pharmacological mechanism of anti-cancer drugs［J］. Cancer Lett，2020，483：127-136.

施引文献(1)

期刊类型引用(0)

其他类型引用(1)

资源附件(0)

计量

文章访问数: 488
HTML全文浏览量: 17
PDF下载量: 1061
被引次数: 1

半胱氨酸代谢途径调控与肿瘤治疗新策略

计量

出版历程

Regulation of cysteine metabolism and new strategies for cancer treatment

期刊类型引用(0)

其他类型引用(1)

计量

出版历程

目录